In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Overcoming Disaster: What Biotechs Do When A Lead Asset Fails

Executive Summary

Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.

You may also be interested in...

Financings Of The Fortnight: Haircuts And Postponements Increasing As IPO Burst Slows Down

The IPO boom of 2013 is showing signs of slowing, while class of 2012 companies are seeing stock prices decline. Plus news on recent financings by Relypsa, Synta Pharmaceuticals, ArGEN-X and Karyopharm Therapeutics.

With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies

Joseph Schlessinger’s insights into receptor tyrosine kinases (RTKs) led to small-molecule treatments and huge success at Sugen and Plexxikon. Schlessinger’s latest venture, Kolltan Pharmaceuticals, had little trouble raising $75 million, but powering up a pipeline of antibodies to target novel RTKs has proven more challenging.

AstraZeneca Opts Out Of Targacept Schizophrenia Program

Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts